Celsion Co.

New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing… The post Celsion Corporation Announces Company Name Change to Imunon, Inc. appeared first on DKODING... » Mehr auf dkoding.in

New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines » Mehr auf globenewswire.com

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment… The post Celsion Completes Enrollment of the Phase I/II OVAT... » Mehr auf dkoding.in